India, Aug. 12 -- Dermata Therapeutics, Inc. (DRMA) announced financial results for the second quarter ended June 30, 2026, alongside a corporate update highlighting its transition into a commercial-stage skincare company.
The San Diego-based firm is preparing to launch its first direct-to-consumer product, Tome Foundational Treatment, on August 25, 2026.
Second quarter results showed a net loss of $2.97 million, or $0.74 per diluted share, widening from $1.70 million, or $1.66 per diluted share in Q2 2025.
Operating expenses rose to $3.0 million from $1.8 million a year earlier, driven by higher legal, marketing, and commercialization costs.
Cash and cash equivalents stood at $4.4 million at quarter-end. The company expects current cas...